VALZ‐Pilot: High‐dose valacyclovir treatment in patients with early‐stage Alzheimer's disease

INTRODUCTION: Herpes simplex virus (HSV) may be involved in Alzheimer's disease (AD) pathophysiology. The antiviral valacyclovir inhibits HSV replication. METHODS: This phase‐II pilot trial involved valacyclovir administration (thrice daily, 500 mg week 1, 1000 mg weeks 2–4) to persons aged ≥ 6...

Descripción completa

Detalles Bibliográficos
Autores principales: Weidung, Bodil, Hemmingsson, Eva‐Stina, Olsson, Jan, Sundström, Torbjörn, Blennow, Kaj, Zetterberg, Henrik, Ingelsson, Martin, Elgh, Fredrik, Lövheim, Hugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919248/
https://www.ncbi.nlm.nih.gov/pubmed/35310522
http://dx.doi.org/10.1002/trc2.12264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919248/
https://www.ncbi.nlm.nih.gov/pubmed/35310522
http://dx.doi.org/10.1002/trc2.12264

Ejemplares similares